2
Clinical Trials associated with CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AML
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML
/ Not yet recruitingPhase 1IIT Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).
100 Clinical Results associated with CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)
100 Translational Medicine associated with CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)
100 Patents (Medical) associated with CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)
100 Deals associated with CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech)